HK1201265A1 - Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity btk - - Google Patents

Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity btk -

Info

Publication number: HK1201265A1
Authority: HK; Hong Kong
Prior art keywords: pyridone; btk; aza; inhibitors; heteroaryl
Prior art date: 2011-11-03

Application number

HK15101799.4A

Other languages

English (en)

Chinese (zh)

Inventor

James John Crawford

Daniel Fred Ortwine

Binqing Wei

Wendy B Young

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-03

Filing date

2015-02-18

Publication date

2015-08-28

2015-02-18 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2015-08-28 Publication of HK1201265A1 publication Critical patent/HK1201265A1/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

HK15101799.4A 2011-11-03 2015-02-18 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity btk - HK1201265A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161555393P	2011-11-03	2011-11-03
PCT/US2012/063194 WO2013067274A1 (en)	2011-11-03	2012-11-02	Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number	Publication Date
HK1201265A1 true HK1201265A1 (en)	2015-08-28

Family

ID=47146779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15101799.4A HK1201265A1 (en)	2011-11-03	2015-02-18	Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity btk -

Country Status (34)

Country	Link
US (10)	US8716274B2 (uk)
EP (5)	EP4019508A1 (uk)
JP (5)	JP5976827B2 (uk)
KR (2)	KR20160003328A (uk)
CN (2)	CN107011348B (uk)
AR (2)	AR088641A1 (uk)
AU (5)	AU2012332365B2 (uk)
CA (1)	CA2853975C (uk)
CL (1)	CL2014001103A1 (uk)
CO (1)	CO6950472A2 (uk)
CR (1)	CR20140194A (uk)
CY (1)	CY1117097T1 (uk)
DK (2)	DK3002284T3 (uk)
EA (1)	EA023263B1 (uk)
ES (3)	ES2555168T3 (uk)
HK (1)	HK1201265A1 (uk)
HR (2)	HRP20151442T1 (uk)
HU (2)	HUE044959T2 (uk)
IL (1)	IL232060A (uk)
IN (1)	IN2014CN03250A (uk)
LT (1)	LT3002284T (uk)
MA (1)	MA35819B1 (uk)
MX (2)	MX361807B (uk)
PE (1)	PE20141586A1 (uk)
PL (3)	PL3521288T3 (uk)
PT (2)	PT2773638E (uk)
RS (2)	RS54505B1 (uk)
SG (1)	SG11201401992YA (uk)
SI (2)	SI2773638T1 (uk)
TR (1)	TR201909849T4 (uk)
TW (4)	TWI609868B (uk)
UA (1)	UA111756C2 (uk)
WO (1)	WO2013067274A1 (uk)
ZA (1)	ZA201804727B (uk)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA111756C2 (uk) *	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
JP5976828B2 (ja) *	2011-11-03	2016-08-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物
KR101815360B1 (ko) *	2013-07-03	2018-01-04	에프. 호프만-라 로슈 아게	헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물
JP2016535764A (ja) *	2013-10-04	2016-11-17	ビヨンドオンコロジーファーマシューティカルエルエルシー	ブルトンのチロシンキナーゼの阻害剤
EP3077384B1 (en) *	2013-12-05	2017-09-06	F. Hoffmann-La Roche AG	Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
CN106922146B (zh)	2014-10-02	2020-05-26	豪夫迈·罗氏有限公司	用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
JP6368043B2 (ja) *	2014-10-27	2018-08-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	三環式ラクタム化合物の製造法
CN106188063A (zh) *	2015-05-08	2016-12-07	中国科学院上海药物研究所	用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
UY36875A (es)	2015-09-02	2017-03-31	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
WO2017070708A1 (en)	2015-10-23	2017-04-27	Array Biopharma, Inc.	2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
BR112018016842A2 (pt) *	2016-02-19	2018-12-26	Novartis Ag	compostos de piridona tetracíclica como antivirais
EP4049660A1 (en) *	2016-02-29	2022-08-31	F. Hoffmann-La Roche AG	Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
EP3448861B1 (en)	2016-04-28	2021-04-21	F. Hoffmann-La Roche AG	A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
CN108101905A (zh) *	2016-11-24	2018-06-01	中国科学院上海药物研究所	嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
JP2020511462A (ja)	2016-12-03	2020-04-16	ジュノーセラピューティクスインコーポレイテッド	キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
WO2018111902A1 (en)	2016-12-12	2018-06-21	Multivir Inc.	Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
TWI766176B (zh) *	2016-12-15	2022-06-01	瑞士商赫孚孟拉羅股份公司	製備btk抑制劑之方法
US11053238B2 (en)	2016-12-22	2021-07-06	Betta Pharmaceuticals Co., Ltd.	Benzimidazole derivatives, preparation methods and uses thereof
TW201836642A (zh)	2017-03-24	2018-10-16	美商建南德克公司	治療自體免疫及發炎疾病的方法
CN107445981B (zh) *	2017-08-25	2018-06-22	牡丹江医学院	一种用于防治***的活性化合物
KR102613433B1 (ko) *	2017-10-11	2023-12-13	주식회사 대웅제약	신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
JP7100125B2 (ja)	2017-10-27	2022-07-12	フレゼニウス・カビ・オンコロジー・リミテッド	リボシクリブおよびその塩の改善された調製のためのプロセス
US11100492B2 (en) *	2018-02-19	2021-08-24	Peter Garrett	General purpose re-loadable card aggregation implementation
TWI801517B (zh)	2018-03-12	2023-05-11	加拿大商愛彼特生物製藥公司	經取代的2-吡啶酮三環化合物、其類似物及其使用方法
US20210113568A1 (en)	2018-04-27	2021-04-22	Ono Pharmaceutical Co., Ltd.	PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CR20210045A (es)	2018-07-25	2021-06-18	Novartis Ag	Inhibidores de inflamasoma nlrp3
KR102328682B1 (ko) *	2018-08-27	2021-11-18	주식회사 대웅제약	신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
US20220362357A1 (en)	2018-08-31	2022-11-17	Stichting Radboud Universitair Medisch Centrum	Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
EP3867242A1 (en)	2018-10-15	2021-08-25	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
TW202033523A (zh) *	2019-01-17	2020-09-16	美商愛彼特生物製藥股份有限公司	經取代的多環羧酸、其類似物及使用其之方法
CN113423401A (zh)	2019-01-22	2021-09-21	豪夫迈·罗氏有限公司	使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和***性红斑狼疮的方法
CN113939292A (zh) *	2019-02-25	2022-01-14	广州麓鹏制药有限公司	Btk及其突变体的抑制剂
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020210508A1 (en)	2019-04-09	2020-10-15	Nurix Therapeutics, Inc.	3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en)	2019-05-17	2022-03-23	Nurix Therapeutics, Inc.	Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
US20220363689A1 (en)	2019-10-05	2022-11-17	Newave Pharmaceutical Inc.	Inhibitor of btk and mutants thereof
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4055019A1 (en) *	2019-11-08	2022-09-14	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11820781B2 (en)	2019-12-04	2023-11-21	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
EP4107154A4 (en)	2020-02-20	2024-02-28	Hutchison Medipharma Ltd	HETEROARYL HETEROCYCLIC COMPOUNDS AND THEIR USES
MX2022010513A (es)	2020-02-28	2022-09-21	Genentech Inc	Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
KR20220163986A (ko)	2020-04-03	2022-12-12	제넨테크, 인크.	브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법
CN115715291A (zh) *	2020-06-18	2023-02-24	上海华汇拓医药科技有限公司	布鲁顿酪氨酸激酶抑制剂及其制备方法
US20230295109A1 (en) *	2020-08-04	2023-09-21	Hoffmann-La Roche Inc.	Pyridinone compounds for the treatment of autoimmune disease
WO2022036171A1 (en) *	2020-08-14	2022-02-17	Newave Pharmaceutical Inc.	Dosage form compositions comprising an inhibitor of btk and mutants thereof
BR112023002031A2 (pt)	2020-08-14	2023-03-07	Novartis Ag	Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
IL301275A (en) *	2020-09-21	2023-05-01	Hutchison Medipharma Ltd	Heterocyclic heteroaryl compounds and their uses
US20230382900A1 (en)	2020-10-30	2023-11-30	Newave Pharmaceutical Inc.	Inhibitors of btk
US20240058457A1 (en)	2020-12-20	2024-02-22	Newave Pharmaceutical Inc.	Btk degrader
WO2022212893A1 (en)	2021-04-02	2022-10-06	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
KR20240004918A (ko)	2021-05-05	2024-01-11	에프. 호프만-라 로슈 아게	Btk 억제제 제조 공정
CN113603685A (zh) *	2021-07-23	2021-11-05	都创(上海)医药开发有限公司	Fenebrutinib化合物的晶型及其制备方法和用途
WO2023110970A1 (en)	2021-12-14	2023-06-22	Netherlands Translational Research Center Holding B.V	Macrocyclic btk inhibitors
WO2023137225A1 (en) *	2022-01-17	2023-07-20	Newave Pharmaceutical Inc.	Btk degrader
WO2023143491A1 (zh) *	2022-01-28	2023-08-03	和记黄埔医药（上海）有限公司	7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法
US20240067627A1 (en)	2022-08-03	2024-02-29	Novartis Ag	Nlrp3 inflammasome inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5583024A (en)	1985-12-02	1996-12-10	The Regents Of The University Of California	Recombinant expression of Coleoptera luciferase
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja)	1995-04-13	1996-12-24	Mitsubishi Chem Corp	光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en)	1997-09-19	2003-08-05	Promega Corporation	Thermostable luciferases and methods of production
CA2453113A1 (en)	2001-07-12	2003-01-23	Avecia Limited	Microencapsulated catalyst, methods of preparation and methods of use thereof
WO2005014599A1 (en)	2003-06-04	2005-02-17	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en)	2003-06-30	2005-01-20	Cellular Genomics, Inc.	Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2006017295A2 (en)	2004-07-12	2006-02-16	Idun Pharmaceuticals, Inc.	Tetrapeptide analogs
CA2587192A1 (en)	2004-11-10	2006-05-18	Cgi Pharmaceuticals, Inc.	Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
KR101357524B1 (ko)	2005-03-10	2014-02-03	질레드 코네티컷 인코포레이티드	특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
AU2006302415B2 (en)	2005-10-07	2012-09-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
AR063946A1 (es)	2006-09-11	2009-03-04	Cgi Pharmaceuticals Inc	Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20080839A1 (es)	2006-09-11	2008-08-23	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US7838523B2 (en)	2006-09-11	2010-11-23	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
KR101315610B1 (ko) *	2006-09-22	2013-10-10	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제 억제제
CL2008002793A1 (es) *	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
EP2205564B1 (en) *	2007-10-23	2014-07-30	F. Hoffmann-La Roche AG	Novel kinase inhibitors
US8426441B2 (en)	2007-12-14	2013-04-23	Roche Palo Alto Llc	Inhibitors of bruton's tyrosine kinase
SI2242749T1 (sl) *	2008-02-05	2013-07-31	F.Hoffmann-La Roche Ag	Novi piridinoni in piridazinoni
US7683064B2 (en)	2008-02-05	2010-03-23	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
AU2009244291B2 (en)	2008-05-06	2014-02-13	Genentech, Inc.	Substituted amides, method of making, and use as Btk inhibitors
EP2297142B1 (en) *	2008-06-24	2015-10-14	F. Hoffmann-La Roche AG	Novel substituted pyridin-2-ones and pyridazin-3-ones
RU2507202C2 (ru)	2008-07-02	2014-02-20	Ф.Хоффманн-Ля Рош Аг	Новые фенилпиразиноны в качестве ингибиторов киназы
CA2636807A1 (en)	2008-07-04	2010-01-04	Steven Splinter	Methods for obtaining cyclopamine
JP5318952B2 (ja)	2008-07-15	2013-10-16	エフ．ホフマン−ラロシュアーゲー	新規なフェニル−イミダゾピリジン類及びピリダジン類
US8598174B2 (en)	2008-11-12	2013-12-03	Genetech, Inc.	Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) *	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
SG175287A1 (en) *	2009-04-24	2011-11-28	Hoffmann La Roche	Inhibitors of bruton's tyrosine kinase
WO2010126960A1 (en) *	2009-04-29	2010-11-04	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
DK2473049T3 (en) *	2009-09-04	2019-04-01	Biogen Ma Inc	INHIBITORS OF BRUTON'S TYROSINKINASE
CA3034600C (en) *	2010-05-07	2020-11-10	Genentech, Inc.	Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es)	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
US9249123B2 (en)	2010-09-01	2016-02-02	Genentech, Inc.	Pyridinones/pyrazinones, method of making, and method of use thereof
JP5842004B2 (ja)	2010-09-01	2016-01-13	ジーアイリードコネチカットインコーポレーテッドＧｉｌｅａｄＣｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ．	ピリダジノン、その製造方法及びその使用方法
KR101585753B1 (ko)	2011-05-17	2016-01-14	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
PE20140865A1 (es)	2011-08-17	2014-07-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
US8669251B2 (en) *	2011-11-03	2014-03-11	Genentech, Inc.	8-fluorophthalazin-1(2H)-one compounds
JP5976828B2 (ja)	2011-11-03	2016-08-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物
UA111756C2 (uk) *	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
KR101815360B1 (ko) *	2013-07-03	2018-01-04	에프. 호프만-라 로슈 아게	헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물
EP3077384B1 (en) *	2013-12-05	2017-09-06	F. Hoffmann-La Roche AG	Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
EP4049660A1 (en) *	2016-02-29	2022-08-31	F. Hoffmann-La Roche AG	Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase

2012
- 2012-02-11 UA UAA201405799A patent/UA111756C2/uk unknown
- 2012-11-02 PT PT127838373T patent/PT2773638E/pt unknown
- 2012-11-02 US US13/667,133 patent/US8716274B2/en not_active Ceased
- 2012-11-02 EP EP21171114.8A patent/EP4019508A1/en active Pending
- 2012-11-02 HU HUE15188086A patent/HUE044959T2/hu unknown
- 2012-11-02 EP EP15188086.1A patent/EP3002284B1/en active Active
- 2012-11-02 ES ES12783837.3T patent/ES2555168T3/es active Active
- 2012-11-02 SI SI201230367T patent/SI2773638T1/sl unknown
- 2012-11-02 KR KR1020157036122A patent/KR20160003328A/ko not_active Application Discontinuation
- 2012-11-02 PL PL19152979T patent/PL3521288T3/pl unknown
- 2012-11-02 PT PT15188086T patent/PT3002284T/pt unknown
- 2012-11-02 TW TW101140919A patent/TWI609868B/zh active
- 2012-11-02 PE PE2014000638A patent/PE20141586A1/es active IP Right Grant
- 2012-11-02 IN IN3250CHN2014 patent/IN2014CN03250A/en unknown
- 2012-11-02 CA CA2853975A patent/CA2853975C/en active Active
- 2012-11-02 RS RS20160001A patent/RS54505B1/en unknown
- 2012-11-02 DK DK15188086.1T patent/DK3002284T3/da active
- 2012-11-02 MX MX2015003514A patent/MX361807B/es unknown
- 2012-11-02 RS RS20190888A patent/RS59016B1/sr unknown
- 2012-11-02 EP EP22157147.4A patent/EP4050012A1/en active Pending
- 2012-11-02 WO PCT/US2012/063194 patent/WO2013067274A1/en active Application Filing
- 2012-11-02 AU AU2012332365A patent/AU2012332365B2/en active Active
- 2012-11-02 CN CN201710227680.4A patent/CN107011348B/zh active Active
- 2012-11-02 ES ES19152979T patent/ES2898938T3/es active Active
- 2012-11-02 CN CN201280065965.8A patent/CN104125959B/zh active Active
- 2012-11-02 HU HUE12783837A patent/HUE028019T2/en unknown
- 2012-11-02 PL PL12783837T patent/PL2773638T3/pl unknown
- 2012-11-02 EP EP12783837.3A patent/EP2773638B1/en active Active
- 2012-11-02 SI SI201231643T patent/SI3002284T1/sl unknown
- 2012-11-02 ES ES15188086T patent/ES2738329T3/es active Active
- 2012-11-02 SG SG11201401992YA patent/SG11201401992YA/en unknown
- 2012-11-02 JP JP2014541114A patent/JP5976827B2/ja active Active
- 2012-11-02 KR KR1020147014661A patent/KR101659193B1/ko active IP Right Grant
- 2012-11-02 TW TW106130019A patent/TWI652270B/zh active
- 2012-11-02 AR ARP120104128A patent/AR088641A1/es active IP Right Grant
- 2012-11-02 LT LTEP15188086.1T patent/LT3002284T/lt unknown
- 2012-11-02 TW TW109129648A patent/TW202124384A/zh unknown
- 2012-11-02 EA EA201490858A patent/EA023263B1/ru unknown
- 2012-11-02 MX MX2014005331A patent/MX2014005331A/es active IP Right Grant
- 2012-11-02 PL PL15188086T patent/PL3002284T3/pl unknown
- 2012-11-02 EP EP19152979.1A patent/EP3521288B1/en active Active
- 2012-11-02 DK DK12783837.3T patent/DK2773638T3/en active
- 2012-11-02 TR TR2019/09849T patent/TR201909849T4/tr unknown
- 2012-11-02 TW TW107141781A patent/TWI701250B/zh active
2014
- 2014-03-13 US US14/207,966 patent/US8921353B2/en active Active
- 2014-04-10 IL IL232060A patent/IL232060A/en active IP Right Grant
- 2014-04-28 CO CO14090476A patent/CO6950472A2/es active IP Right Grant
- 2014-04-28 CR CR20140194A patent/CR20140194A/es unknown
- 2014-04-29 CL CL2014001103A patent/CL2014001103A1/es unknown
- 2014-05-27 MA MA37075A patent/MA35819B1/fr unknown
- 2014-09-08 US US14/479,529 patent/US9238655B2/en active Active
2015
- 2015-02-18 HK HK15101799.4A patent/HK1201265A1/xx unknown
- 2015-08-24 JP JP2015165300A patent/JP2016028046A/ja not_active Withdrawn
- 2015-11-17 US US14/943,552 patent/US9782405B2/en active Active
- 2015-12-31 HR HRP20151442TT patent/HRP20151442T1/hr unknown
2016
- 2016-01-04 CY CY20161100003T patent/CY1117097T1/el unknown
- 2016-12-15 AU AU2016273930A patent/AU2016273930B2/en active Active
2017
- 2017-08-31 US US15/693,022 patent/US10045983B2/en active Active
2018
- 2018-01-04 JP JP2018000309A patent/JP6571215B2/ja active Active
- 2018-03-05 AU AU2018201557A patent/AU2018201557B2/en active Active
- 2018-06-27 US US16/020,270 patent/US20190194203A1/en not_active Abandoned
- 2018-07-16 ZA ZA2018/04727A patent/ZA201804727B/en unknown
- 2018-10-30 US US16/175,278 patent/USRE48239E1/en active Active
2019
- 2019-02-14 JP JP2019024668A patent/JP2019108342A/ja not_active Withdrawn
- 2019-07-18 HR HRP20191307TT patent/HRP20191307T1/hr unknown
- 2019-08-16 AU AU2019216728A patent/AU2019216728B2/en active Active
- 2019-10-31 US US16/670,898 patent/US20200062769A1/en not_active Abandoned
- 2019-12-23 AR ARP190103844A patent/AR117501A2/es unknown
2020
- 2020-04-22 AU AU2020202707A patent/AU2020202707B2/en active Active
- 2020-07-02 JP JP2020114594A patent/JP2020183397A/ja not_active Withdrawn
- 2020-08-24 US US17/001,205 patent/US20210079002A1/en not_active Abandoned
2022
- 2022-12-20 US US18/069,099 patent/US20230279012A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2020183397A (ja)	2020-11-12
JP2014532762A (ja)	2014-12-08
HRP20191307T1 (hr)	2019-10-18
CR20140194A (es)	2014-06-03
AU2019216728A1 (en)	2019-09-05
AU2018201557B2 (en)	2019-09-19
CA2853975C (en)	2020-02-25
TWI701250B (zh)	2020-08-11
AR088641A1 (es)	2014-06-25
EP2773638B1 (en)	2015-10-07
DK2773638T3 (en)	2015-10-19
PT3002284T (pt)	2019-07-17
EP3002284A1 (en)	2016-04-06
PL3002284T3 (pl)	2019-11-29
CN107011348A (zh)	2017-08-04
IL232060A (en)	2016-02-29
US20160228432A1 (en)	2016-08-11
CL2014001103A1 (es)	2014-10-03
KR101659193B1 (ko)	2016-09-22
SI2773638T1 (sl)	2015-12-31
JP2016028046A (ja)	2016-02-25
TW201906845A (zh)	2019-02-16
CN104125959B (zh)	2017-05-03
AU2012332365A1 (en)	2014-05-01
MA35819B1 (fr)	2014-12-01
ZA201804727B (en)	2023-03-29
NZ624021A (en)	2016-09-30
PL2773638T3 (pl)	2016-03-31
DK3002284T3 (da)	2019-07-29
HRP20151442T1 (hr)	2016-01-29
AR117501A2 (es)	2021-08-11
TW202124384A (zh)	2021-07-01
WO2013067274A1 (en)	2013-05-10
RS54505B1 (en)	2016-06-30
TWI652270B (zh)	2019-03-01
US20190194203A1 (en)	2019-06-27
AU2020202707B2 (en)	2021-09-02
CN104125959A (zh)	2014-10-29
EP2773638A1 (en)	2014-09-10
EA201490858A1 (ru)	2014-08-29
ES2898938T3 (es)	2022-03-09
ES2738329T3 (es)	2020-01-22
JP2019108342A (ja)	2019-07-04
US20230279012A1 (en)	2023-09-07
PL3521288T3 (pl)	2021-12-27
EP4050012A1 (en)	2022-08-31
RS59016B1 (sr)	2019-08-30
US9782405B2 (en)	2017-10-10
US20210079002A1 (en)	2021-03-18
PT2773638E (pt)	2016-01-12
AU2016273930A1 (en)	2017-01-12
MX361807B (es)	2018-12-17
LT3002284T (lt)	2019-08-12
JP5976827B2 (ja)	2016-08-24
US9238655B2 (en)	2016-01-19
KR20140096097A (ko)	2014-08-04
TW201326175A (zh)	2013-07-01
US20180071286A1 (en)	2018-03-15
IL232060A0 (en)	2014-05-28
IN2014CN03250A (uk)	2015-07-03
EP3002284B1 (en)	2019-05-22
USRE48239E1 (en)	2020-10-06
US20130116235A1 (en)	2013-05-09
AU2020202707A1 (en)	2020-05-14
US10045983B2 (en)	2018-08-14
US20140194408A1 (en)	2014-07-10
US8716274B2 (en)	2014-05-06
SG11201401992YA (en)	2014-05-29
PE20141586A1 (es)	2014-10-25
CA2853975A1 (en)	2013-05-10
BR112014010459A2 (pt)	2017-04-18
KR20160003328A (ko)	2016-01-08
EA023263B1 (ru)	2016-05-31
HUE028019T2 (en)	2016-11-28
UA111756C2 (uk)	2016-06-10
SI3002284T1 (sl)	2019-08-30
US20200062769A1 (en)	2020-02-27
MX2014005331A (es)	2014-05-28
CY1117097T1 (el)	2017-04-05
JP6571215B2 (ja)	2019-09-04
AU2012332365B2 (en)	2016-09-15
ES2555168T3 (es)	2015-12-29
JP2018080193A (ja)	2018-05-24
EP3521288A1 (en)	2019-08-07
EP3521288B1 (en)	2021-09-08
HUE044959T2 (hu)	2019-12-30
US20140378432A1 (en)	2014-12-25
AU2019216728B2 (en)	2020-04-09
TR201909849T4 (tr)	2019-07-22
EP4019508A1 (en)	2022-06-29
CO6950472A2 (es)	2014-05-20
AU2016273930B2 (en)	2018-03-08
TWI609868B (zh)	2018-01-01
AU2018201557A1 (en)	2018-03-22
CN107011348B (zh)	2020-01-10
TW201741315A (zh)	2017-12-01
US8921353B2 (en)	2014-12-30

Publication	Publication Date	Title
ZA201804727B (en)	2023-03-29	Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK1243417A1 (zh)	2018-07-13	吡啶酮和氮雜吡啶酮化合物及使用方法
EP2903613A4 (en)	2016-04-20	INHIBITORS OF IRAQ4 ACTIVITY
HK1205111A1 (en)	2015-12-11	8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity btk 8--1(2h)-
EP2663565A4 (en)	2014-07-02	HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
HK1208026A1 (en)	2016-02-19	Heteroaryl inhibitors of pde4 pde4
EP2903617A4 (en)	2016-05-18	INHIBITORS OF IRAQ4 ACTIVITY
HK1197234A1 (en)	2015-01-09	Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity btk
HK1203954A1 (en)	2015-11-06	Heteroaryl compounds and methods of use thereof
HK1203494A1 (en)	2015-10-30	Heteroaryl compounds and methods of use thereof
EP2847193A4 (en)	2015-11-18	HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
TH1401002406B (th)	2016-06-07	สารประกอบเฮทเทอโรเอริล ไพริโดน และ อะซา-ไพริโดนในรูปสารยับยั้งของ btk แอคตีวิตี้